Compare DAO & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAO | DVAX |
|---|---|---|
| Founded | 2006 | 1996 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2019 | 2004 |
| Metric | DAO | DVAX |
|---|---|---|
| Price | $10.95 | $15.44 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $26.50 |
| AVG Volume (30 Days) | 106.8K | ★ 4.3M |
| Earning Date | 02-19-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 155.59 | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $798,421,874.00 | $330,514,000.00 |
| Revenue This Year | $5.23 | $24.63 |
| Revenue Next Year | $13.46 | $15.85 |
| P/E Ratio | $68.17 | ★ N/A |
| Revenue Growth | N/A | ★ 26.73 |
| 52 Week Low | $6.30 | $9.20 |
| 52 Week High | $11.82 | $15.49 |
| Indicator | DAO | DVAX |
|---|---|---|
| Relative Strength Index (RSI) | 64.15 | 89.03 |
| Support Level | $8.38 | $10.78 |
| Resistance Level | $11.49 | $15.43 |
| Average True Range (ATR) | 0.50 | 0.14 |
| MACD | 0.28 | 0.34 |
| Stochastic Oscillator | 81.67 | 98.97 |
Youdao Inc develops and markets software applications. It engages in developing technologies to provide learning content, applications, and solutions. The firm operates in three segments: Learning services, Smart devices, and Online marketing services. The majority of its revenue comes from the Learning services segment, which generates revenues from online courses, mainly including Youdao Premium Courses, NetEase Cloud Classroom, and China University MOOC. The learning products segment includes sales of smart devices such as the Youdao Dictionary Pen and the Youdao Pocket Translator. Geographically, all of its revenue is generated from the People's Republic of China.
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.